REGENXBIO Inc. (RGNX) Reaches $49.69 After 8.00% Down Move; Baxter International Has 0.97 Sentiment

May 16, 2018 - By Hazel Jackson


The stock of REGENXBIO Inc. (NASDAQ:RGNX) is a huge mover today! The stock decreased 2.47% or $1.26 during the last trading session, reaching $49.69. About 224,009 shares traded. REGENXBIO Inc. (NASDAQ:RGNX) has risen 43.49% since May 16, 2017 and is uptrending. It has outperformed by 31.94% the S&P500.The move comes after 9 months negative chart setup for the $1.59B company. It was reported on May, 16 by We have $45.71 PT which if reached, will make NASDAQ:RGNX worth $126.96M less.

Baxter International Inc (BAX) investors sentiment is 0.97 in Q4 2017. It’s the same as in 2017Q3. The ratio is neither positive nor negative, as only 331 active investment managers increased and started new equity positions, while 343 sold and trimmed stakes in Baxter International Inc. The active investment managers in our database now hold: 441.20 million shares, up from 439.80 million shares in 2017Q3. Also, the number of active investment managers holding Baxter International Inc in top ten equity positions decreased from 15 to 9 for a decrease of 6. Sold All: 32 Reduced: 311 Increased: 250 New Position: 81.

Ratings analysis reveals 50% of Baxter’s analysts are positive. Out of 2 Wall Street analysts rating Baxter, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. BAX was included in 2 notes of analysts from October 13, 2016. RBC Capital Markets maintained the shares of BAX in report on Wednesday, October 26 with “Sector Perform” rating. The company was initiated on Thursday, October 13 by Wells Fargo.

The stock increased 0.62% or $0.44 during the last trading session, reaching $70.89. About 941,418 shares traded. Baxter International Inc. (BAX) has risen 25.16% since May 16, 2017 and is uptrending. It has outperformed by 13.61% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 5 selling transactions for $5.13 million activity.

Third Point Llc holds 16.8% of its portfolio in Baxter International Inc. for 36.00 million shares. Sector Gamma As owns 694,438 shares or 7.54% of their US portfolio. Moreover, Veritas Asset Management Llp has 5.01% invested in the company for 9.98 million shares. The New York-based 13D Management Llc has invested 4.36% in the stock. Healthcor Management L.P., a New York-based fund reported 1.73 million shares.

Baxter International Inc. provides a portfolio of renal and hospital products. The company has market cap of $37.96 billion. The firm operates through two divisions, Hospital Products and Renal. It has a 55.08 P/E ratio. The Hospital Products segment makes intravenous solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products.

Analysts await Baxter International Inc. (NYSE:BAX) to report earnings on July, 25. They expect $0.71 earnings per share, up 12.70% or $0.08 from last year’s $0.63 per share. BAX’s profit will be $380.20 million for 24.96 P/E if the $0.71 EPS becomes a reality. After $0.70 actual earnings per share reported by Baxter International Inc. for the previous quarter, Wall Street now forecasts 1.43% EPS growth.

More news for Baxter International Inc. (NYSE:BAX) were recently published by:, which released: “Baxter (BAX) Announces US FDA Clearance of New Spectrum IQ Infusion System” on May 14, 2018.‘s article titled: “Loeb’s Third Point LLC Enters Adobe (ADBE), EA (EA), Wynn (WYN) (more…) – 13F” and published on May 15, 2018 is yet another important article.

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The rating was initiated by Bank of America on Monday, October 12 with “Buy”. The company was initiated on Monday, October 12 by Piper Jaffray. The firm has “Buy” rating by Chardan Capital Markets given on Tuesday, October 20. The company was initiated on Tuesday, October 13 by Morgan Stanley.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $1.59 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

Baxter International Inc. (NYSE:BAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: